Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.55 |
| ▸ | HTR6 | P50406 | 6/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PPME1 | Q9Y570 | 3/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | APEH | P13798 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20839195 | 0.88 | BRD4 (0.48) | BRD4HTR6PTGER4CCR6 | |
| SCHEMBL13745848 | 0.88 | BRD4 (0.58) | BRD4HTR6CCR6 | |
| SCHEMBL1773252 | 0.81 | BRD4 (0.58) | BRD4HTR6METCYP2C19HTR1A | |
| SCHEMBL1043519 | 0.81 | BRD4 (0.58) | BRD4HTR6METCYP2C19IRAK4 | |
| SCHEMBL1266871 | 0.81 | BRD4 (0.58) | BRD4HTR6METCYP2C19HTR1A | |
| SCHEMBL1799967 | 0.81 | BRD4 (0.67) | BRD4HTR6METCYP2C19 | |
| SCHEMBL1887325 | 0.81 | BRD4 (0.58) | BRD4HTR6METCYP2C19HTR1A | |
| SCHEMBL1050312 | 0.81 | BRD4 (0.64) | BRD4HTR6METCYP2C19 | |
| SCHEMBL1585180 | 0.81 | BRD4 (0.52) | BRD4HTR6METCYP2C19HTR1A | |
| SCHEMBL1487601 | 0.79 | BRD4 (0.41) | BRD4HTR6PTGER4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2454257-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| EP-2038272-A2 | PYRIDINONYL PDK1 INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1599475-A2 | JNK INHIBITORS | Eisai Co., Ltd. (JP) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | BRD4 337/4885HTR6 3526/4885PTGER4 3850/4885 |
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | BRD4 1384/4885HTR6 2354/4885PTGER4 3087/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | BRD4 1339/4885HTR6 2381/4885PTGER4 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.